JUBILANT PHARMOVA LIMITED

BSE: JUBLPHARMA530019ISIN INE700A01033

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹1,067.15+55.10 (+5.44%)

as of 18 Sep 2026

52W high: ₹1,183.90
52W low: ₹783.75
Off 52W high: -9.86%
1M return: +22.86%
3M return: +10.51%
6M return: +28.29%
1Y return: -4.28%
20D avg volume: 26,871
50 DMA: ₹947.83
200 DMA: ₹958.62

Key ratios Consolidated

Market cap: ₹16,998 Cr
Current price: ₹1,067.15
52W high / low: ₹1,183.90 / ₹783.75
Face value: ₹1.00
P/E: 48.37
P/B: —
EPS (TTM): ₹22.06
Book value / share: —
ROE: —
ROCE: 6.40%
Operating margin: —
Net margin: —
Debt / equity: 0.45
Net debt: ₹1,952 Cr
Interest cover: 3.90
Dividend yield: 0.47%
Dividend / share (TTM): ₹5.00
Payout: 22.67%
Cash conversion cycle: 47.1 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,229	2,290	2,122	1,966	1,901	1,929	1,822	1,752	1,732	175.86	1,677	1,680
	19.90	23.70	20.50	9.80	12.00	11.90	9.20	21.70	14.00	1.44	35.80	9.90
	2,163	2,124	2,010	1,780	1,758	1,731	1,681	1,615	1,642	166.12	1,625	1,601
	638.30	642.80	592.10	564.90	520.50	584.00	467.00	469.00	465.30	49.73	431.50	464.40
	86.90	84.50	82.00	73.60	73.00	84.80	81.20	69.30	61.80	5.39	71.80	58.40
	753.50	766.90	706.40	636.20	591.10	590.60	560.10	564.30	552.90	55.50	581.50	531.80
	54.20	56.50	56.10	50.20	49.00	52.70	55.60	61.00	71.00	7.30	71.30	66.10
	127.30	116.80	120.70	104.80	98.10	95.20	91.30	91.40	90.70	10.10	94.60	96.60
	479.20	470.50	410.30	392.30	401.80	366.70	399.80	343.80	365.60	40.48	341.70	349.40
	86.40	189.70	133.20	196.20	154.50	209.40	149.70	158.70	103.80	11.18	87.90	89.00
	0.00	-13.70	-39.70	-5.80	0.00	-3.30	-18.90	-14.20	395.90	-16.89	0.00	0.00
	86.40	176.00	93.50	190.40	154.50	206.10	130.80	144.50	499.70	-5.71	87.90	89.00
	30.00	56.70	37.60	70.40	51.90	54.70	29.80	41.90	17.90	0.81	34.60	35.90
	56.40	119.30	55.80	119.90	102.50	151.30	100.70	102.50	481.80	-6.18	66.40	62.10
	3.57	7.55	3.52	7.59	6.49	9.71	6.37	6.47	30.44	-3.69	4.22	3.94
Key metrics
	267.90	349.30	270.30	345.40	301.60	354.00	277.70	296.90	661.40	11.69	253.80	251.70
	12.00%	15.30%	12.70%	17.60%	15.90%	18.40%	15.20%	16.90%	38.20%	6.60%	15.10%	15.00%
	2.50%	5.20%	2.60%	6.10%	5.40%	7.80%	5.50%	5.80%	27.80%	-3.50%	4.00%	3.70%
	—	1.80%	—	2.10%	—	2.40%	—	—	—	—	—	—
	17.30%	18.70%	16.50%	12.20%	9.80%	996.80%	8.60%	4.30%	—	—	—	—
	-45.00%	-21.20%	-44.60%	17.00%	-78.70%	2,548.20%	51.70%	65.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	8,608	8,280	7,234	670.29	6,282	6,059	6,099	9,154	9,111	7,558	6,006
	73.90	66.00	56.80	6.87	38.33	82.28	17.64	47.43	35.74	40.03	24.86
	8,077	7,672	6,670	645.63	6,248	5,501	5,235	7,957	7,963	6,739	5,294
	2,438	2,320	1,985	182.13	1,666	1,349	1,349	3,119	3,283	2,678	1,929
	327.00	313.10	297.10	24.12	252.22	201.62	167.63	276.58	240.91	242.82	—
	2,863	2,701	2,268	221.60	2,166	2,043	1,923	2,128	1,926	1,556	—
	217.00	211.80	240.30	27.23	188.20	145.49	184.10	287.41	219.81	284.28	341.11
	469.60	440.40	368.60	38.19	554.03	381.70	348.95	461.93	370.90	415.05	291.40
	1,752	1,675	1,476	144.54	1,462	1,442	—	—	—	—	—
	605.50	673.60	621.60	31.53	72.35	640.43	881.06	1,245	1,184	859.08	737.64
	-59.20	-59.20	359.50	-16.89	-56.82	0.00	-21.23	-34.64	-280.23	0.00	0.00
	546.30	614.40	981.10	14.64	15.53	640.43	859.83	1,211	903.81	859.08	737.64
	194.70	216.60	144.30	9.78	92.66	217.43	297.22	312.29	326.80	224.66	163.02
	351.40	397.50	836.30	7.27	-64.88	413.02	835.61	898.24	577.01	634.42	574.62
	22.23	25.15	52.99	4.87	-3.83	26.00	36.05	56.39	36.86	—	—
Key metrics
	1,233	1,267	1,590	80.06	757.76	1,168	1,393	1,960	1,495	1,558	1,370
	14.32%	15.30%	22.00%	11.90%	12.10%	19.30%	22.80%	21.40%	16.40%	20.60%	22.80%
	4.08%	4.80%	11.60%	1.10%	-1.00%	6.80%	13.70%	9.80%	6.30%	8.40%	9.60%
	—	6.40%	11.50%	—	—	—	—	—	—	—	—
	—	14.40%	979.30%	-89.30%	3.70%	-0.60%	-33.40%	0.50%	20.50%	25.80%	—
	—	-52.50%	11,403.40%	111.20%	-115.70%	-50.60%	-7.00%	55.70%	-9.00%	10.40%	—
	—	-222.30	-43.50	—	—	—	—	—	—	—	—
	—	3.09	1.28	—	—	—	—	—	—	—	—
	—	0.45	0.39	—	—	—	—	—	—	—	—
	—	1,952	1,349	—	—	—	—	—	—	—	—
	—	47.1	51.3	—	—	—	—	—	—	—	—
Balance sheet
	—	15,523	12,756	—	—	—	—	—	—	—	—
	—	4,109	3,510	—	—	—	—	—	—	—	—
	—	1,267	1,088	—	—	—	—	—	—	—	—
	—	1,070	891.50	—	—	—	—	—	—	—	—
	—	1,232	1,129	—	—	—	—	—	—	—	—
	—	249.00	220.60	—	—	—	—	—	—	—	—
	—	3,510	2,132	—	—	—	—	—	—	—	—
	—	1,234	1,005	—	—	—	—	—	—	—	—
	—	2,539	2,165	—	—	—	—	—	—	—	—
	—	3,220	2,437	—	—	—	—	—	—	—	—
	—	247.80	286.60	—	—	—	—	—	—	—	—
	—	2,972	2,150	—	—	—	—	—	—	—	—
	—	7,096	6,239	—	—	—	—	—	—	—	—
Cash flow
	—	1,227	1,072	—	—	—	—	—	—	—	—
	—	-1,260	487.70	—	—	—	—	—	—	—	—
	—	94.90	-1,453	—	—	—	—	—	—	—	—
	—	1,449	1,116	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	67.10	70.30	67.30	66.40	59.50	217.30	196.00	165.70	166.70	205.80	175.20	186.30
	0.10	0.50	0.40	0.80	0.70	17.90	18.40	43.80	19.50	50.10	19.00	18.40
	57.40	58.00	57.60	58.70	53.70	211.70	205.70	192.90	186.20	214.40	196.50	204.50
	0.00	0.00	0.00	0.00	0.00	78.00	76.80	62.20	65.50	74.10	69.10	94.90
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	1.50	3.90	1.50
	28.30	24.80	29.20	26.60	23.20	50.80	52.10	51.40	48.70	46.50	49.90	46.10
	0.90	0.90	0.90	2.50	3.00	7.00	7.40	7.80	7.60	8.10	8.30	7.10
	1.40	1.30	1.60	1.60	1.50	13.40	13.30	13.30	13.10	12.70	12.30	11.90
	26.80	31.00	25.90	28.00	26.00	59.80	56.70	62.00	56.30	55.20	54.20	53.30
	9.80	12.80	10.10	8.50	6.50	23.50	8.70	16.60	—	41.50	-2.30	0.20
	0.00	-8.70	0.00	0.00	0.00	0.00	—	—	-11.20	—	—	—
	9.80	4.10	10.10	8.50	6.50	23.50	8.70	16.60	-11.20	41.50	-2.30	0.20
	2.50	53.10	3.50	56.50	2.40	9.90	3.40	6.10	1.00	9.00	0.10	0.60
	7.30	57.20	6.60	-6.40	5.80	13.60	5.30	10.50	-10.20	32.50	-2.40	-0.40
	0.46	3.59	0.42	-3.02	0.36	0.86	0.33	0.66	-0.64	2.05	-0.15	-0.03
Key metrics
	12.10	6.30	12.60	12.60	11.00	43.90	29.40	37.70	9.50	62.30	18.30	19.20
	18.00%	9.00%	18.70%	19.00%	18.50%	20.20%	15.00%	22.80%	5.70%	30.30%	10.40%	10.30%
	10.90%	81.40%	9.80%	-9.60%	9.70%	6.30%	2.70%	6.30%	-6.10%	15.80%	-1.40%	-0.20%
	—	0.20%	—	0.50%	—	1.20%	—	—	—	—	—	—
	12.80%	-67.60%	-65.70%	-59.90%	-64.30%	5.60%	11.90%	-11.10%	—	—	—	—
	25.90%	320.60%	24.50%	-161.00%	156.90%	-58.20%	320.80%	2,725.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	271.10	263.50	745.70	784.70	810.12	87.75	2,710	3,140	3,439	3,343	2,623
	1.80	2.40	99.60	103.40	137.89	125.87	47.88	173.23	78.00	46.21	51.90
	231.70	228.00	796.50	846.40	868.67	131.37	2,484	3,013	3,333	3,022	2,560
	0.00	0.00	282.50	310.00	396.30	—	1,329	1,683	1,875	1,644	1,244
	0.00	0.00	0.00	6.50	14.81	—	66.23	109.46	131.47	154.05	—
	108.90	103.80	203.00	190.00	167.27	49.21	220.67	264.90	265.71	264.42	—
	5.20	7.30	29.80	29.90	18.52	30.59	101.80	136.20	128.96	135.17	174.25
	5.90	6.00	53.10	48.30	43.25	6.25	99.97	107.40	86.48	82.60	81.13
	111.70	110.90	234.80	222.70	225.07	45.32	—	—	—	—	371.70
	41.20	37.90	48.80	41.70	79.34	82.25	273.17	300.54	183.43	367.69	114.52
	-8.70	-8.70	-11.20	—	—	—	—	-1.70	—	—	—
	32.50	29.20	37.60	41.70	79.34	82.25	273.17	298.84	183.43	367.69	114.52
	115.60	9.30	18.40	10.10	29.46	3.75	58.69	22.30	35.80	104.25	35.33
	64.70	63.20	19.20	31.60	49.88	78.50	214.48	321.14	147.63	263.44	79.19
	1.45	3.97	1.21	1.99	3.13	4.93	13.47	20.16	9.27	—	—
Key metrics
	43.60	42.50	120.50	119.90	141.11	119.09	474.94	542.44	398.87	585.46	369.90
	16.08%	16.10%	16.20%	15.30%	17.40%	135.70%	17.50%	17.30%	11.60%	17.50%	14.10%
	23.87%	24.00%	2.60%	4.00%	6.20%	89.50%	7.90%	10.20%	4.30%	7.90%	3.00%
	—	1.50%	2.60%	—	—	—	—	—	—	—	—
	—	-64.70%	-5.00%	-3.10%	823.20%	-96.80%	-13.70%	-8.70%	2.90%	27.50%	—
	—	229.20%	-39.20%	-36.60%	-36.50%	-63.40%	-33.20%	117.50%	-44.00%	232.70%	—
	—	74.10	114.20	—	—	—	—	—	—	—	—
	—	1.48	7.06	—	—	—	—	—	—	—	—
	—	0.02	0.13	—	—	—	—	—	—	—	—
	—	39.70	293.50	—	—	—	—	—	—	—	—
	—	20.9	139.0	—	—	—	—	—	—	—	—
Balance sheet
	—	2,433	2,910	—	—	—	—	—	—	—	—
	—	50.90	484.20	—	—	—	—	—	—	—	—
	—	10.30	12.60	—	—	—	—	—	—	—	—
	—	23.80	206.30	—	—	—	—	—	—	—	—
	—	0.00	232.40	—	—	—	—	—	—	—	—
	—	—	32.20	—	—	—	—	—	—	—	—
	—	95.40	514.80	—	—	—	—	—	—	—	—
	—	8.70	154.80	—	—	—	—	—	—	—	—
	—	56.70	310.30	—	—	—	—	—	—	—	—
	—	50.00	306.10	—	—	—	—	—	—	—	—
	—	0.00	73.30	—	—	—	—	—	—	—	—
	—	50.00	232.80	—	—	—	—	—	—	—	—
	—	2,312	2,318	—	—	—	—	—	—	—	—
Cash flow
	—	93.60	135.60	—	—	—	—	—	—	—	—
	—	34.00	-2.30	—	—	—	—	—	—	—	—
	—	-129.90	-156.80	—	—	—	—	—	—	—	—
	—	19.50	21.40	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -31.23%
Sales CAGR 5Y: -37.26%
Sales CAGR 10Y: —
Profit CAGR 3Y: +8.21%
Profit CAGR 5Y: -21.68%
Profit CAGR 10Y: —
Sales YoY (TTM): -57.54%
Profit YoY (TTM): +83.81%

Consolidated

Sales CAGR 3Y: +9.64%
Sales CAGR 5Y: +6.31%
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: -13.81%
Profit CAGR 10Y: —
Sales YoY (TTM): +16.27%
Profit YoY (TTM): -23.11%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 47.68%

Holder	Type	Holding	Previous	Change
SPB TRUSTEE COMPANY PVT LTD	Promoter Group	20.08%	—	—
HSB TRUSTEE COMPANY PVT LTD	Promoter Group	19.00%	—	—
REKHA JHUNJHUNWALA	Public	6.43%	—	—
MILLER HOLDINGS PTE LTD	Promoter Group	3.28%	—	—
BANDHAN SMALL CAP FUND	Public	3.21%	—	—
MAV MANAGEMENT ADVISORS LLP	Promoter Group	3.15%	—	—
GOVERNMENT PENSION FUND GLOBAL	Public	3.10%	—	—
EAST BRIDGE CAPITAL MASTER FUND I LTD	Public	2.53%	—	—
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND	Public	2.41%	—	—
Theleme India Master Fund Limited	Public	1.89%	—	—
QUANT MUTUAL FUND - QUANT SMALL CAP FUND	Public	1.85%	—	—
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	1.25%	—	—
ABAKKUS EMERGING OPPORTUNITIES FUND-1	Public	1.15%	—	—
SBI LIFE INSURANCE CO. LTD	Public	1.11%	—	—
NIKITA RESOURCES PRIVATE LIMITED	Promoter Group	0.97%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Update on USFDA Spokane11 Sep 2026 · Company Update / General
Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST1 Sep 2026 · Company Update / General
Newspaper Publication - Relodgement and KYC Updation29 Aug 2026 · Company Update / Newspaper Publication
Receipt of Show Cause Notice - Jubilant Generics Limited28 Aug 2026 · Company Update / General
Scrutinizer''s Report26 Aug 2026 · AGM/EGM / AGM
Outcome of AGM26 Aug 2026 · AGM/EGM / AGM
USFDA Approval for Line 3, Contract manufacturing facility, Spokane, USA23 Aug 2026 · Company Update / General
Outcome of Postal Ballot17 Aug 2026 · AGM/EGM / Postal Ballot
Scrutinizer''s Report17 Aug 2026 · AGM/EGM / Postal Ballot
Newspaper Publications11 Aug 2026 · Company Update / Newspaper Publication
Press Release and presentation10 Aug 2026 · Company Update / Press Release / Media Release
Un-audited Financial Results for the Quarter ended June 30, 202610 Aug 2026 · Result / Financial Results
outcome of Board meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Investors/ Analysts Meeting5 Aug 2026 · Company Update / Analyst / Investor Meet
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited Standalone ....5 Aug 2026 · Company Update / Board Meeting Rescheduled
Newspaper advertisements titled ''Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information''2 Aug 2026 · Company Update / General
Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2026-26, if approved by the members at the ensuing AGM1 Aug 2026 · Company Update / General
Intimation regarding letter dispatched to the shareholders whose email IDs are not registered, for AGM Notice, TDS Communication and Annual Report of the Company for FY 2025-261 Aug 2026 · Company Update / General
Please find enclosed herewith the Business Responsibility and Sustainability Report for the financial year 2025-261 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find attached herewith the Notice of 48th Annual General Meeting alongwith the Annual Report for the Financial Year 2025-26. The 48th AGM of the Company will be held on Wednesday, ....1 Aug 2026 · AGM/EGM / AGM
Pursuant to Regulations 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Annual Report along with Notice of AGM ....1 Aug 2026 · Others / Reg. 34 (1) Annual Report
Pursuant to Regulations 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Annual Report along with Notice of AGM ....1 Aug 2026 · Others / Reg. 34 (1) Annual Report
Submission of Copies of Newspaper Advertisement relating to Notice to Shareholders - Transfer of equity shares/dividend to IEPF30 Jul 2026 · Company Update / General
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....30 Jul 2026 · Board Meeting / Board Meeting
Announcement under Regulation 30 (LODR) - Communication sent to shareholders relating to notice of transfer to IEPF29 Jul 2026 · Company Update / General
Submission of copies of Newspaper Publications - Annual General Meeting of Jubilant Pharmova Limited scheduled to be held on Wednesday, August 26, 2026 through Video Conferencing/Other ....29 Jul 2026 · Company Update / General
Newspaper publication - Dispatch of Postal Ballot19 Jul 2026 · Company Update / Newspaper Publication
Notice of Postal Ballot dated July 18, 202618 Jul 2026 · AGM/EGM / Postal Ballot
Rectification order from the Income Tax Department16 Jul 2026 · Company Update / General
Approval for Grant of Stock Options/RSUs/PSUs16 Jul 2026 · Company Update / General
Receipt of Rectification Order16 Jul 2026 · Others
Compliances under Regulation 74 (5) of SEBI (DP) Regulation, 2018, for the quarter ended on June 30, 20262 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
newspaper publication1 Jul 2026 · Company Update / Newspaper Publication
Receipt of Rectification order30 Jun 2026 · Company Update / General
Intimation for the closure of trading window for the quarter ending on June 30, 2026.29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Tentative approval for Panto-prazole Sodium DR26 Jun 2026 · Company Update / General
Rectification Order in the matter of Jubilant Generics Limited, Wholly owned step down subsidiary24 Jun 2026 · Company Update / General
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 19, 2026 for HSB Trustee Company ....19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Completion of USFDA inspection19 Jun 2026 · Company Update / General
USFDA update29 May 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 5.0000	24 Jul 2026	24 Jul 2026	—
Final Dividend - Rs. - 5.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 5.0000	2 Aug 2024	2 Aug 2024	—

Board meetings

10 Aug 2026 Board Meeting - Financial Results
7 Aug 2026 Board Meeting - Financial Results